In this issue:
Long-term adalimumab for CD after infliximab nonresponse or intolerance
Andecaliximab (anti-MMP9) induction therapy for UC
Acute MI and HF risks increased in patients with IBD
Mesalazine for preventing acute occurrence in uncomplicated diverticular disease
Probiotics + aminosalicylic acid in UC
Men with IBD use more erectile dysfunction medications
Elderly- vs. nonelderly-onset UC
Ineffectiveness with immunomodulator monotherapy for IBD
Factors contributing to indeterminate QFT-GIT results in IBD
Please login below to download this issue (PDF)